) recently announced encouraging data on Ultibro Breezhaler from
the development programme, IGNITE, at the European Respiratory
Society (ERS) Annual Congress in Barcelona, Spain.
The IGNITE programme comprises 11 studies. The first eight
studies were completed in 2012.
New analyses of the data revealed that patients suffering from
chronic obstructive pulmonary disease (COPD) and treated with
Ultibro Breezhaler showed significant improvement in lung
function, reduction in the shortness of breath/breathlessness and
better quality of life as compared to placebo.
We note that Novartis already has Arcapta Neohaler/Onbrez
Breezhaler and Seebri Breezhaler in its product portfolio for
treating COPD patients.
Ultibro Breezhaler is a fixed-dose combination of Onbrez
Breezhaler and Seebri Breezhaler. Novartis is developing Ultibro
Breezhaler as a once daily treatment for COPD, in a single-dose
We remind investors that Novartis received a positive opinion
from the CHMP on Ultibro Breezhaler as a maintenance
bronchodilator treatment to relieve symptoms in adult patients
with COPD in Jul 2013.
Meanwhile, Novartis also has another pipeline candidate,
BYM338, which is being developed for COPD.
We are encouraged by the pipeline progress at Novartis. We
remind investors that Novartis upped its 2013 guidance based on
solid performance in the first half and lower-than-expected
generic erosion. The delayed entry of generic Diovan Mono (high
blood pressure) in the U.S. continues to positively impact
Novartis now expects sales to increase in the low single
digits in 2013 as compared to the earlier expectation of being in
line with 2012. Sales in the Pharmaceutical Division are expected
to be in line with 2012 compared to the previous estimate of a
low single-digit decline.
Novartis currently carries a Zacks Rank #3 (Hold). Right now,
) and Forest Laboratories Inc. (
) look attractive, each carrying a Zacks Rank #2 (Buy).
FOREST LABS A (FRX): Free Stock Analysis
IRONWOOD PHARMA (IRWD): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
NOVARTIS AG-ADR (NVS): Free Stock Analysis
To read this article on Zacks.com click here.